October 19, 2024 06:00 AM EDT
Weekly

A Q&A with a No­bel Prize win­ner; Pfiz­er meets with Star­board; J&J re­ports Q3 earn­ings; and more

Max Gelman

Senior Editor

Nicole DeFeudis

Editor

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Sage re­ports Phase 2 fail­ure in Hunt­ing­ton's dis­ease, ends drug's de­vel­op­ment

Car­olyn Bertozzi’s lat­est biotech de­buts with $30M seed round and a sug­ary spin on im­munother­a­py

Pfiz­er taps on­col­o­gy head Boshoff as Dol­sten's chief sci­en­tif­ic of­fi­cer suc­ces­sor

Ex­clu­sive: For­mer Pfiz­er com­mer­cial chief An­gela Hwang to join Flag­ship

GSK plots reg­u­la­to­ry fil­ings for PBC itch af­ter pos­i­tive Phase 3 read­out

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times